Business
Stocks To Watch: Infosys, ONGC, Pine Labs, JSW Steel, IndiGo, Tata Capital, And Others
Last Updated:
Stocks to watch: Shares of firms like Infosys, ONGC, Pine Labs, JSW Steel, IndiGo, Tata Capital, and others will be in focus on Thursday’s trade
Stocks To Watch
Stocks to Watch on December 4: Markets saw a volatile session and settled marginally lower, extending the ongoing consolidation phase. Sentiment took a hit as the rupee weakened to a record low of 90.13 against the dollar, raising concerns over higher import costs and triggering FII outflows. Caution ahead of the MPC meeting and mixed global cues further weighed on investor mood.
During the session, the Nifty slipped below the key short-term support of the 20-DEMA near the 25,950 level, but a recovery in the final hour helped it reclaim this mark. Analysts advised investors to manage position sizes carefully and stay selective—preferring IT and pharma stocks for long trades, while looking at rate-sensitive sectors on dips.
Meanwhile, here are some of the top stocks to watch today:
ONGC:
The government has approved a one-year extension for Arun Singh as chairman of ONGC. His three-year term was set to end on December 6. Singh, who retired as chairman of Bharat Petroleum Corporation in 2022, was appointed to revive ONGC at a time when the company was facing years of declining output.
Reliance Industries:
Reliance Strategic Business Ventures, a wholly owned subsidiary of Reliance Industries, along with Surrey County Cricket Club, announced a partnership in the Oval Invincibles franchise in The Hundred. This follows a deal under which the two entities will hold 49 per cent and 51 per cent stakes, respectively, with ownership transferred from the England and Wales Cricket Board.
Infosys:
The IT major is witnessing rising client interest in India-based global capability centres (GCCs). Several new engagements are now beginning with proposals to set up GCCs before expanding into wider technology partnerships, a senior executive said on Wednesday. The company is also stepping up efforts to capture a larger share of the expanding GCC market.
Pine Labs:
The fintech firm reported a consolidated net profit of ₹5.97 crore in Q2 FY26, compared with a loss of ₹32.01 crore in Q2 FY25. Revenue from operations rose 17.82 per cent year-on-year to ₹649.9 crore from ₹551.57 crore.
Cipla:
In partnership with Stempeutics Research, Cipla announced its entry into orthobiologic medicine with the launch of Ciplostem—an allogeneic mesenchymal stromal cell (MSC) therapy for knee osteoarthritis.
JSW Steel:
Sajjan Jindal-led JSW Steel and JFE Steel Corporation will jointly own and operate the steel business of Bhushan Power and Steel Ltd (BPSL) under an equal partnership. The Japanese steelmaker will acquire a 50 per cent stake in the joint venture for ₹15,750 crore.
InterGlobe Aviation (IndiGo):
India’s largest airline has cancelled more than 300 flights over the past two days and delayed hundreds more as a growing pilot shortage disrupted operations following the implementation of new flight duty time limitation (FDTL) rules, aviation industry sources said.
RailTel Corporation of India:
The company informed exchanges that it has received a work order from the Mumbai Metropolitan Region Development Authority for a project worth ₹48.78 crore, excluding tax.
Indian Energy Exchange:
India’s leading electricity exchange recorded a monthly electricity traded volume (excluding TRAS) of 11,409 MU in November 2025, reflecting a 17.7 per cent year-on-year increase. A total of 4.74 lakh Renewable Energy Certificates were traded during the month.
Bank of Maharashtra:
The offer-for-sale (OFS) of the bank closed for subscription on Wednesday at a floor price of ₹54 per share. At this price, the government stands to raise about ₹2,492 crore by divesting its 6 per cent stake. Before the OFS, the government held 79.60 per cent in the bank. Post dilution to 73.6 per cent, the bank will meet the minimum public shareholding (MPS) norm of 25 per cent.
Tata Capital:
Sebi has passed a settlement order related to a suo motu settlement application filed by the company under the Sebi (Settlement Proceedings) Regulations, 2018. Tata Capital also said it has paid the settlement amount of ₹14,40,000.
Lemon Tree Hotels:
The company has signed a licence agreement for “Lemon Tree Hotel” at Pacific Mall, Jaipur. The property will be managed by Carnation Hotels Private Limited, a wholly owned subsidiary of Lemon Tree Hotels Limited.
Vintage Coffee and Beverages:
The company has launched 100 per cent pure instant coffee in India as part of its expansion into the fast-growing coffee and beverages market. Following the opening of the Vintage Coffee Café in Nerul, Navi Mumbai in September 2024, and the successful launch of two brands in the conventional roast and ground coffee segment on select e-commerce platforms, the instant coffee launch further strengthens its product portfolio and consumer reach.
Disclaimer: The views and investment tips by experts in this News18.com report are their own and not those of the website or its management. Users are advised to check with certified experts before taking any investment decisions.
Click here to add News18 as your preferred news source on Google. December 04, 2025, 07:59 IST
Read More
Last Updated:
Every $10 rise in global crude oil prices could shave around 0.5 percentage points off India’s GDP growth, say experts
India imports nearly 50 percent of crude oil from the Middle East
Every $10 rise in global crude oil prices could shave around 0.5 percentage points off India’s GDP growth, underscoring the country’s heavy reliance on imported oil and vulnerability to global energy volatility, Vandana Bharti, Research Head–Commodity at SMC Global Securities, told ANI.
In an interview with ANI, Bharti said escalating geopolitical tensions in West Asia pose a significant economic risk for India as crude prices climb and supply chains face potential disruptions.
“Every $10 increase in crude oil prices impacts India’s GDP by roughly 0.5%. We have already seen prices rise by about $10–$15 recently, and the economic impact will eventually reflect in growth numbers,” she said.
West Asia tensions driving oil prices higher
The surge in oil prices follows intensifying tensions involving the United States, Israel and Iran, particularly around the Strait of Hormuz — a critical maritime corridor through which roughly 20–25% of global oil shipments pass.
Bharti said the conflict has injected additional uncertainty into global energy markets and added what she described as a “war premium” to crude prices.
“It’s not just about the possibility of the Strait of Hormuz closing. Insurance costs and freight charges are rising, and shipments are being rerouted. All these factors add a war premium to crude oil prices and increase market uncertainty,” she said.
Risks extend beyond shipping
According to Bharti, the risks go beyond maritime routes and extend to energy infrastructure itself.
“Energy sites such as crude oil facilities and LNG plants are potential targets. There are also concerns about seabed cables and other critical infrastructure. So the threat is not only to energy supply but also to broader global trade and connectivity,” she noted.
Crude prices rise sharply
Oil prices have already surged as tensions intensified in the region.
Bharti said crude climbed from around $69 per barrel to nearly $78 per barrel within a week.
“In just one week we have seen prices move from about $69 to $78 per barrel. If tensions persist, crude could rise further to around $85–$87 per barrel in the coming days,” she said.
India’s reliance on Middle Eastern crude
India remains particularly vulnerable to such price shocks due to its heavy dependence on imported oil.
Bharti noted that roughly half of India’s crude imports come from the Middle East, and many domestic refineries are specifically configured to process Middle Eastern crude grades.
“India imports nearly 50% of its crude from the Middle East, so any disruption in the region directly impacts supply availability and pricing,” she said.
India maintains strategic petroleum reserves that can help cushion short-term disruptions, but Bharti emphasised that these are primarily meant for emergencies.
“We have reserves that can last about 25–30 days in emergency situations, but the structural dependence on Middle Eastern supply remains,” she said.
She added that even brief supply disruptions could trigger volatility across Asian financial markets.
“Even a two-week disruption could create significant volatility in Asia. We are already seeing pressure on currencies, equity outflows and rising economic uncertainty,” Bharti said.
Diversification may cushion the impact
Bharti said India could mitigate some risks by diversifying crude supply sources.
“Russia has been offering crude at discounted prices, so India may increase purchases from Russia or other suppliers if required. Adjusting supply chains and renegotiating trade arrangements can provide some relief,” she said.
She also pointed out that members of the Organization of the Petroleum Exporting Countries (OPEC) may attempt to stabilise prices, although security concerns could limit immediate production increases.
Impact on fertilisers and agriculture
Higher crude prices could also ripple into other sectors of the economy.
Bharti warned that rising energy costs may push up fertiliser prices and agricultural input costs, potentially affecting the upcoming kharif crop season.
“Higher energy costs could make fertilisers and farm inputs more expensive, which may increase the cost of cultivation for farmers,” she said.
Renewables gain strategic importance
Bharti added that the ongoing geopolitical tensions highlight the need for countries to accelerate the transition to renewable energy.
“Events like this are a wake-up call. Governments may increasingly prioritise renewable energy such as solar to reduce dependence on volatile fossil-fuel supply routes,” she said.
Click here to add News18 as your preferred news source on Google.
Follow News18 on Google. Join the fun, play games on News18. Stay updated with all the latest business news, including market trends, stock updates, tax, IPO, banking finance, real estate, savings and investments. To Get in-depth analysis, expert opinions, and real-time updates. Also Download the News18 App to stay updated.
March 06, 2026, 08:16 IST
Read More
The supply chain risk designation of the artificial intelligence firm is a first for a US company.
Source link
Thomas Fuller | SOPA Images | Lightrocket | Getty Images
UniQure needs to run another study to prove that its gene therapy “actually helps people with Huntington’s disease,” a senior U.S. Food and Drug Administration official said on a call with reporters Thursday.
The official, who requested anonymity before discussing sensitive information, confirmed the agency has asked the company to run a placebo controlled trial of its treatment, which is administered directly into the brain. UniQure has said that type of study isn’t ethical because it would require putting people under general anesthesia for hours, a characterization the official disputed.
“So what is really going on? UniQure is the latest company to make a failed therapy for Huntington’s patients,” the official said. “They likely acknowledge or understand at some deep level that their trial failed years ago, and instead of doing the right thing and running the correct clinical study, UniQure is performing a distorted or manipulated comparison in the mind of FDA.”
The comments mark the latest development in a messy public spat between UniQure and the FDA, and as the agency comes under fire for a number of recent drug approval application rejections, including some where companies have accused it of going back on previous guidance. FDA Commissioner Marty Makary in an interview with CNBC’s Becky Quick last week seemingly criticized UniQure’s gene therapy for Huntington’s disease. Makary didn’t name UniQure but described its treatment.
UniQure then accused the FDA of reversing its stance that the company’s clinical trial data would be sufficient to seek approval. UniQure’s study used an outside database to measure how patients with Huntington’s disease might decline without treatment, known as an external control. UniQure has said it wouldn’t be feasible to run a true randomized, double-blind placebo-controlled study, considered the gold standard, because it wouldn’t be ethical to make people undergo a sham hours-long brain surgery.
The FDA official said the agency “never agreed to accept this distorted comparison” and the FDA “never makes such assurances.” Instead, the “FDA will always say, ‘Well, we have to see the data when we get it.'”
UniQure didn’t immediately comment.
The company’s stock rose more than 10% on Thursday and has fallen 58% this year as of Thursday afternoon.
Turkiye’s apparel exports drop 6% to $16.3 bn in 2025
How Costly Is A $10 Oil Spike For India’s Economy?
Jayson Tatum, 10 months after Achilles injury, expected to return to Celtics Friday vs Mavericks: report
What are Iran’s ballistic missile capabilities?
India Us Trade Deal: Fresh look at India-US trade deal? May be ‘rebalanced’ if circumstances change, says Piyush Goyal – The Times of India
Attock Cement’s acquisition approved | The Express Tribune
-
Fashion1 week agoPolicy easing drives Argentina’s garment import surge in 2025
-
Politics1 week agoWhat are Iran’s ballistic missile capabilities?
-
Business7 days ago
India Us Trade Deal: Fresh look at India-US trade deal? May be ‘rebalanced’ if circumstances change, says Piyush Goyal – The Times of India
-
Business1 week ago
Attock Cement’s acquisition approved | The Express Tribune
-
Politics1 week agoUS arrests ex-Air Force pilot for ‘training’ Chinese military
-
Business6 days agoGreggs to reveal trading amid pressure from cost of living and weight loss drugs
-
Sports6 days agoLPGA legend shares her feelings about US women’s Olympic wins: ‘Gets me really emotional’
-
Fashion7 days agoTexwin Spinning showcasing premium cotton yarn range at VIATT 2026